The Conversation: The backlash against Johnson & Johnson's COVID-19 vaccine is real and risky—here's exactly how to make its rollout a successMarket Watch • 03/10/21
Here's What Investors Should Know About Johnson & Johnson's FDA AuthorizationThe Motley Fool • 03/10/21
Week 10 MDA Breakout Stocks - March 2021: Short-Term Picks To Give You An EdgeSeeking Alpha • 03/06/21
Vaccine Miracles: Does JNJ Kill the Profit Path for MRNA and NVAX?Zacks Investment Research • 03/05/21
4 Stocks to Watch as FDA Action Plan Stresses MedTech DigitizationZacks Investment Research • 03/05/21
Why the FDA's Coronavirus Variant Guidance Is Great News for Pfizer, Moderna, and Johnson & JohnsonThe Motley Fool • 03/05/21